Patents by Inventor Dianqing Wu
Dianqing Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890283Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.Type: GrantFiled: October 8, 2021Date of Patent: February 6, 2024Assignee: Yale UniversityInventors: Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang
-
Publication number: 20230190897Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: ApplicationFiled: October 6, 2022Publication date: June 22, 2023Inventors: Dianqing Wu, Lee Sun
-
Publication number: 20230181582Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with viral infections, such as those due to coronaviruses that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries often associated with these infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/AP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof, The present invention also provides devices for administering the compositions.Type: ApplicationFiled: May 20, 2021Publication date: June 15, 2023Applicants: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Publication number: 20230026808Abstract: The disclosure includes methods of preventing, ameliorating, and/or treating ischemia-reperfusion injury (IRI), including but not limited to post brain stroke, using a MAP3K2/MAP3K3 inhibitor. In another aspect, the present disclosure relates to methods of preventing, ameliorating, and/or treating a lung injury related to a coronavirus infection, acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) using a MAP3K2/MAP3K3 inhibitor. The disclosure further comprises compositions, and kits comprising compositions useful within the disclosure.Type: ApplicationFiled: November 17, 2020Publication date: January 26, 2023Inventors: Dianqing WU, Qianying YUAN, Wenwen TANG
-
Patent number: 11497747Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: GrantFiled: March 17, 2022Date of Patent: November 15, 2022Assignees: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Patent number: 11497799Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: GrantFiled: August 1, 2019Date of Patent: November 15, 2022Assignee: YALE UNIVERSITYInventors: Dianqing Wu, Le Sun
-
Publication number: 20220202816Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: ApplicationFiled: March 17, 2022Publication date: June 30, 2022Applicants: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Publication number: 20220162294Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: ApplicationFiled: February 7, 2022Publication date: May 26, 2022Inventors: Dianqing WU, Bo CHEN, Hai WU
-
Patent number: 11304947Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: GrantFiled: May 20, 2021Date of Patent: April 19, 2022Assignees: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Patent number: 11267875Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: GrantFiled: October 20, 2016Date of Patent: March 8, 2022Assignee: Yale UniversityInventors: Dianqing Wu, Bo Chen, Hai Wu
-
Publication number: 20220040177Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.Type: ApplicationFiled: October 8, 2021Publication date: February 10, 2022Inventors: Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang
-
Publication number: 20210361650Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: ApplicationFiled: May 20, 2021Publication date: November 25, 2021Applicants: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Patent number: 11166953Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.Type: GrantFiled: April 17, 2018Date of Patent: November 9, 2021Assignee: YALE UNIVERSITYInventors: Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang
-
Publication number: 20210121459Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.Type: ApplicationFiled: April 17, 2018Publication date: April 29, 2021Inventors: Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang
-
Publication number: 20200179510Abstract: The present invention relates to the discovery that inhibition of the interaction between Dickkopf2 (DKK2) and Low-Density Lipoprotein (LDL) Receptor Related Protein 5 (LRP5) and/or inhibition of LRP5 suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of an inhibiting agent that blocks the interaction between DKK2 and LRP5, methods of treating cancer by administering to a patient an effective amount of a LRP5 depleting agent, methods for providing anti-tumor immunity in a subject, and methods of stimulating a NK and T cell mediated immune response to a cell population or a tissue in a subject. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer.Type: ApplicationFiled: February 16, 2018Publication date: June 11, 2020Inventors: Dianqing WU, Qian XIAO
-
Publication number: 20200093903Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: ApplicationFiled: August 1, 2019Publication date: March 26, 2020Inventors: Dianqing WU, Le SUN
-
Patent number: 10398765Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: GrantFiled: June 30, 2015Date of Patent: September 3, 2019Assignee: Yale UniversityInventors: Dianqing Wu, Le Sun
-
Publication number: 20180230204Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: ApplicationFiled: October 20, 2016Publication date: August 16, 2018Inventors: Dianqing WU, Bo CHEN, Hai WU
-
Publication number: 20180200354Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: ApplicationFiled: June 30, 2015Publication date: July 19, 2018Inventors: Dianqing WU, Le SUN
-
Patent number: 8637506Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: GrantFiled: May 19, 2004Date of Patent: January 28, 2014Assignees: Enzo Biochem, Inc., University of Connecticut, St. Jude's Childrens HospitalInventors: Dianqing Wu, Yazhou Zhang, Peng Liu, Xiaofeng Li, Jie Zhang, Jufang Shan, Dean Engelhardt